UAB Comprehensive Cancer Center Magazine Spring 2016 | Page 4

failed before coming to me,” Dr. Saleh says.“ It’ s extremely difficult for these patients to meet the eligibility criteria. We need to think about phase I studies differently than we have thought about them before. It used to be an end-of-the-line option, and it’ s no longer that. In many cases, it may very well be closer to the front of the line.”
Dr. Saleh’ s message for patients and referring physicians is that phase I studies should be considered sooner rather than later.“ We shouldn’ t wait until the end of the line to refer a patient to a phase I study,” he says.“ We are here to say if you don’ t have an FDA-approved option, consider a phase I trial.”
“ What we can best do for the patient should be our goal. We have a highly trained and compassionate team, all dedicated to this concept of giving the patient the drug called hope.”
Mansoor Saleh, M. D. UAB Comprehensive Cancer Center senior scientist and director of the Phase I Program
The Role of the Cancer Center
The Cancer Center has long been a tremendous supporter of the Phase I Unit and was instrumental in its creation. The program currently has 16 open trials, nearly all of which are oncology-related and more than double from when the program started. Some are studying hematologic malignancies, while others involve solid tumors and the rest are considered“ catch-all.”“ We are ambitious in our goal, but pragmatic and focused in our approach. With our disease-specific as well as catch-all, first-in-human trials, we have something for every patient,” Dr. Saleh says.
“ While the objective of a phase I study is safety, tolerability and pharmacokinetic profile of novel drugs never administered to patients before, we are seeing more and more combination phase I studies, where an FDA-approved agent is delivered with the study agent. In many ways, such phase I trials also offer the real potential for some biologic and clinical activity,” Dr. Saleh says.“ But, it is important to know that we are still in the experimental phase and do not have data to make any claim of benefit.”
The Phase I Unit has a number of trials that are target- or pathway-specific. For example, if researchers are studying a drug’ s effect on a certain gene mutation or cell-survival pathway, only patients with that“ actionable signal” would be eligible for the trial. That target, however, could appear in a number of cancers. Thus, a number of the phase I studies are geared toward a broad range of cancers.
The Phase I Program also has a number of trials involving the human body’ s natural disease fighter – the T-cell.“ There is an entire army of drugs that stimulate the immune system and its T cells,” Dr. Saleh says.“ However, we have not been able to activate the T-cell and help it fight cancer cells effectively, because cancer cells produce proteins and chemicals that inhibit the actions of the T-cell. We now have drugs that activate those T-cells and overcome the inhibitory impact of the tumor cell.” An example of these types of agents are the“ check-point” inhibitors, including, for example, the drug given to former President Jimmy Carter to treat his melanoma.“ In our Phase I Program, we have a number of FDA-approved check-point inhibitors being administered with novel new drugs aimed at activating the cancer-fighting potential of the body’ s own immune mechanism,” Dr. Saleh says.
The challenge with any clinical trial, including phase I studies, is that patients must meet an often extensive list of eligibility criteria. Overall health – termed Performance Status – is an important factor, as are baseline laboratory studies, the stage of the cancer and having measurable target lesions, just to name a few. This goes a long way in explaining why not all patients can qualify for a clinical trial, because the only way to study new agents is to have a strictly defined patient population and to strictly adhere to the protocol.
“ When I see patients in my clinic, many have had five or more prior treatment regimens that have
The Future of Phase I
Dr. Saleh is hopeful that the more patients referred to the Phase I Program, the more clinical trials he and his team will be able to offer.“ Our focus is the patient – for them to have a one-stop shop where everything is done in one place,” he says.“ It’ s the supermarket approach. If everything can be done in one place, it’ s easier and more efficient for the patient.”
For patients as well as referring physicians, UAB’ s Phase I Unit is a unique offering.“ Other institutions offer phase I studies, but not a dedicated phase I program,” Dr. Saleh says.“ We are one of the few academic medical centers – one of the few comprehensive cancer centers – who are doing phase I studies through a cohesive team approach.”
For UAB and the Cancer Center, having a phase I program such as this allows patients access to novel drugs they otherwise would not have. That access allows scientists to expand their research in new and innovative ways.
Dr. Saleh has high hopes for the future of phase I studies at UAB. He envisions the institution eventually having a building solely

PHASE I

First step in testing a new treatment in humans. Determines a drug’ s toxicity, dosage and side effects and usually involves a limited number of patients who would not be helped by other known treatments.
dedicated to phase I clinical research, as well as a program to train young investigators to conduct phase I research.“ Within three years, if we can put more than 100 patients per year on phase I trials and have a repertoire of at least 20 diseasespecific and catch-all trials, where every patient can at least be given the option of a phase I trial, that is what we are aiming for.”
Because as Dr. Saleh firmly believes, it is all about the patient.“ What we can best do for the patient should be our goal,” he says.“ We have a highly trained and compassionate team, all dedicated to this concept of giving the patient‘ the drug called hope.’ We may not be able to help every patient, but we will surely try and give them our best. That is our commitment.”

PHASE II

Focuses on learning whether the new treatment has an anti-cancer effect, i. e., does it shrink the tumor?
For more information, contact 205-996-HOPE or phaseIreferral @ uab. edu

PHASES OF A CLINICAL TRIAL

PHASE III

Compares the results of patients taking the new treatment with results of patients taking standard treatment, i. e., which group has better survival rates and fewer side effects?
4 U A B C O M P R E H E N S I V E C A N C E R C E N T E R # K N O W U A B C C C • U A B. E D U / C A N C E R 5